Fresenius Medical Care North America Significantly Reduces Mortality and Hospitalization for Dialysis Patients
June 21 2016 - 8:30AM
Business Wire
- Company’s 2016 Annual Medical Report
details initiatives that contributed to higher quality and lower
cost care
- Report highlights Fresenius Medical
Care’s focus on improving quality of life for people with
renal-related chronic disease in North America
Fresenius Medical Care North America (FMCNA), the nation’s
leading fully integrated provider of kidney disease-related
products and services, announced today that it has dramatically
improved patient outcomes over the last decade. During the 10-year
period from 2005 to 2015, it reduced mortality per patient-year and
hospitalizations among all of its permanent dialysis patients by 27
and 22 percent, respectively. These outcomes, which are detailed in
the company’s 2016 Annual Medical Report, are a product of the
company’s expansion beyond traditional renal services into care
coordination, as well as its continued industry-leading
technological and clinical innovation and quality improvement
activities.
For example, through Dialysis Hospitalization Reduction (DHR),
local FMCNA interdisciplinary teams use an internally developed
predictive model to identify dialysis patients at risk of needing
frequent hospital care. As part of DHR, dialysis clinic teams
intervene to address the issues that cause health vulnerabilities
for these at-risk patients, resulting in significantly reduced
hospital admissions and hospital days for them.
In addition, FMCNA’s Timely Catheter Reduction focuses on
achieving a usable permanent access for patients who dialyze with a
central venous catheter. The use of a permanent access, such as a
fistula or graft, is associated with better patient outcomes and a
reduction in infections. FMCNA care teams coordinate their services
and follow a clinical pathway that leads to more timely removal of
the catheters.
Through these and other proprietary quality improvement
activities, the company’s clinical teams provide dialysis and
chronic kidney disease patients with care that is most appropriate
for their unique needs, whether they are receiving care in a
dialysis facility, a hospital, an urgent care center, or a vascular
access clinic. The 2016 Annual Medical Report details FMCNA’s suite
of businesses, services, and research, all of which are designed to
provide patients who have renal and other chronic diseases with the
highest level of care and quality of life as possible. In addition,
the report profiles the company’s clinical leaders who are
developing care models and integrating their efforts to promote
holistic patient care, which maximizes clinical quality, safety,
and efficiency.
“This group of talented and dedicated clinical leaders is
fundamentally changing the way in which we are delivering care for
chronically ill individuals,” said Dr. Frank Maddux, FMCNA Chief
Medical Officer and Executive VP, Clinical and Scientific Affairs.
“As a result, we are better able to address our patients’ physical
and psychological needs while being good stewards of health
resources. I am proud that this year’s Annual Medical Report
highlights how the commitment and passion of these leaders across
our entire organization and their teams are driving our clinical
activities toward the highest level of patient outcomes.”
Download the 2016 Annual Medical Report here and visit the FMCNA
Newsroom for more information.
About Fresenius Medical Care North America
Fresenius Medical Care North America is the premier health care
company focused on providing the highest quality care to people
with renal and other chronic conditions. Through its
industry-leading network of dialysis facilities, outpatient cardiac
and vascular labs, and urgent care centers, as well as the
country’s largest practice of hospitalist and post-acute providers,
Fresenius Medical Care provides coordinated health care services at
pivotal care points for hundreds of thousands of chronically ill
customers across the continent. As the world’s largest fully
integrated renal company, it offers specialty pharmacy and
laboratory services, and manufactures and distributes the most
comprehensive line of dialysis equipment, disposable products, and
renal pharmaceuticals. For more information, visit the FMCNA
website at www.freseniusmedicalcare.us. For information about
patient services, visit www.freseniuskidneycare.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160621005061/en/
Fresenius Medical Care North AmericaJon Stone, 781-699-9704Cell:
781-392-4680Jonathan.d.stone@fmc-na.com
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From Apr 2023 to Apr 2024